Cortagen sped sciatic nerve regrowth by 27% in injured rats

What is Cortagen?

Cortagen is the tetrapeptide Ala-Glu-Asp-Pro (AEDP), one of the short-peptide "bioregulators" developed by Khavinson and collaborators. Each peptide in that family is named for the tissue it was purportedly derived from or targets, and for Cortagen that tissue is the cerebral cortex.

A reader weighing a "lowers cortisol, improves sleep" claim first needs to know whether the claim concerns a studied molecule or a marketing narrative built on a name. For Cortagen, the molecule is real and identifiable. The cortisol claim is not supported by anything published on it.

Does Cortagen lower cortisol?

No published study shows that Cortagen lowers cortisol, because no Cortagen study has measured cortisol. The name comes from the cerebral cortex. Cortagen is not derived from cortisol and shares no biosynthetic pathway with it, so the resemblance is a coincidence of nomenclature, not a mechanism.

Treating Cortagen as a cortisol-modulating compound because of how the name sounds is the most common due-diligence failure in forum and blog coverage. Standard peptide-guide coverage asserts that Cortagen lowers cortisol, improves sleep, and speeds training recovery via "HPA axis regulation." None of the three Cortagen studies measures cortisol, ACTH, corticotropin-releasing hormone, sleep architecture, or any HPA-axis marker. The nerve regeneration study measured axonal conduction ^[1], the gene-expression study measured cardiac transcripts ^[2], and the ischemia study measured behavioral recovery and oxidative stress markers in ischemic rat brain ^[3].

A mechanism by which some CNS-active peptides could plausibly influence stress signaling is not evidence that Cortagen does so in a person, and no study bridges that gap. Forum anecdotes such as "I slept better" or "I felt less stressed" are the kind of subjective outcome most sensitive to expectation effects. They do not substitute for a measured cortisol value in a controlled study, and no such study exists for AEDP.

How is Cortagen supposed to work?

Cortagen is proposed to shift gene expression in a tissue-selective way, under the Khavinson bioregulator framework. The framework's working hypothesis is that short peptides derived from specific tissues interact with chromatin or regulatory DNA elements and shift transcription toward patterns seen in younger or healthier tissue.

The closest direct evidence for AEDP is a mouse microarray study. After five days of Cortagen administration, the study screened 15,247 transcripts in cardiac tissue and found 234 clones with significant expression changes, mapping to 110 known genes ^[2].

The screen shows broad transcriptomic activity extending beyond the CNS, which fits the bioregulator hypothesis. It is still gene expression change in mouse heart tissue, not a behavioral, cognitive, or hormonal outcome in a living human. Reading it as evidence of a specific clinical effect, cortisol lowering or otherwise, overstates what a transcriptomic screen can show.

What has Cortagen done in animal studies?

Three preclinical papers make up the entire identified Cortagen literature, covering rat nerve regeneration ^[1], mouse heart gene expression ^[2], and rat brain ischemia ^[3].

Sciatic nerve regeneration in rats. In a rat sciatic nerve transection model, intramuscular Cortagen at 10 µg/kg/day for 10 days increased axonal growth rate by 27% and conduction velocity in regenerating fibers by 40% compared with saline controls ^[1]. The result is a peripheral nerve regeneration finding in surgically injured rats, not a CNS cognitive or stress-related outcome.

Gene expression in mouse hearts. The microarray study found altered expression in 110 known genes after five days of treatment ^[2]. It establishes that AEDP has measurable biological activity in a rodent model, without characterizing what those changes mean functionally.

Chronic brain ischemia in rats. Rats were stratified by hypoxia resistance phenotype. Across both resistance groups, Cortagen accelerated recovery of individual behavior and prevented excessive lipid peroxidation and decline in antioxidant activity in brain tissue ^[3]. The ischemia paper is the most CNS-relevant of the three and the closest thing to a "neuroprotective" finding. It still measured oxidative stress markers and behavioral recovery in an animal model, not sleep quality, subjective stress, or cortisol.

Has Cortagen been tested in humans?

No human trial of Cortagen exists: no RCT, no open-label trial, and no PubMed-indexed clinical study of AEDP. All three animal studies come from overlapping Russian research groups, none has been independently replicated by an outside lab, and none involves human subjects.

Animal-only data from a single research lineage, with no independent replication and no human trials, is the combination a Grade E designation is meant to flag. Grade E does not mean Cortagen does nothing. It means the evidence needed to make a human-relevant claim does not exist yet.

Is there a human dose for Cortagen?

No validated human dose for Cortagen exists. The dosing figures that trace to studies are animal doses, such as the rat protocol from the nerve regeneration paper: 10 µg/kg/day intramuscularly for 10 days ^[1]. That is an animal dose in a specific injury model, and neither the dose nor the route translates directly to a human milligram regimen.

Milligram-based human dosing charts on peptide forums and vendor sites trace to no study. The routes in circulation, intramuscular and subcutaneous injection, are consistent with the preclinical work and with gray-market sourcing. No human pharmacokinetic data exist to inform dose, frequency, or route.

Should Cortagen be stacked with DSIP or BPC-157?

No Cortagen study supports stacking it with DSIP or BPC-157 for sleep or recovery. None of the three studies tested either pairing, and the recommendations are forum convention rather than derived evidence. DSIP's deep-sleep evidence and BPC-157's human evidence cover the other halves of those stacks.

Is Cortagen safe?

No evidence establishes that Cortagen is safe. Reported side effects, including injection-site irritation, transient overstimulation, and headache, are anecdotal and not drawn from any formal adverse-event tracking system. The absence of documented harm in three small rodent studies is not a characterized human safety profile.

Sourcing adds a separate risk. Research-use-only and gray-market products carry unverified purity and sterility, independent of anything AEDP's biology does. How to read a peptide COA explains what a certificate of analysis does and does not verify.

What is still unknown about Cortagen?

Almost everything a human user would need to know about Cortagen is unmeasured:

• Pharmacokinetics. No human pharmacokinetic profile exists.
• Dose-response. No human dose-response data exist.
• Cortisol, sleep, and recovery. No controlled human study has measured cortisol, sleep quality, or training recovery after Cortagen administration.
• Long-term brain effects. Long-term CNS effects in humans are entirely uncharacterized.